基本面優先主動型ETF KNOW 深 滬
已收盤 04-02 16:00:00 美东时间
12.1444
+0.030
+0.24%
華盛通- 最 高12.17
- 今 開12.149
- 成交量 1617股
- 最 低 12.11
- 昨 收 12.1149
- 總市值 607.22万
- 52周最高 12.6743
- 市盈率 靜 --
- 換手率 0.32%
- 52周最低 9.7768
- 委 比 0.00%
- 總股本 50.00万
- 歷史最高 12.6743
- 量 比 0.44
- 振 幅 0.50%
- 歷史最低 7.8742
- 每 手 1
- 風險率 0.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多LIVE MARKETS-Wall Street gains on optimism about Iran conflict
LIVE MARKETS-Wall Street gains on optimism about Iran conflict US equity indexes green: Nasdaq out front, up ~1.3% Cons Disc leads S&P 500 sector gainers; Just Energy, Staples dip Euro STOXX 600 index up ~1.4% Dollar up; gold, bitcoin both up ~2%; US crude down ~4% US 10-Year Treasury yield falls to
03-25 22:37
LIVE MARKETS-Retail investors step back as Middle East tensions rattle markets
LIVE MARKETS-Retail investors step back as Middle East tensions rattle markets Main US indexes green; Nasdaq out front, up ~1% Cons DIsc leads S&P 500 sector gainers; Energy weakest group Euro STOXX 600 index up >1% Dollar up; gold up >1%; bitcoin up >2%; US crude down >4% US 10-Year Treasury yield
03-25 21:56
LIVE MARKETS-Oil just right for Fed hawkishness
LIVE MARKETS-Oil just right for Fed hawkishness Adds blog post STOXX up 1.4% Nearly all European stocks sectors in positive territory S&P futures up 0.8% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research
03-25 18:58
BRIEF-Talzenna Plus Xtandi Significantly Improves Radiographic Progression-Free Survival In Metastatic Prostate Cancer
BRIEF-Talzenna Plus Xtandi Significantly Improves Radiographic Progression-Free Survival In Metastatic Prostate Cancer March 19 (Reuters) - Pfizer Inc PFE.N : TALZENNA PLUS XTANDI SIGNIFICANTLY IMPROVES RADIOGRAPHIC PROGRESSION-FREE SURVIVAL IN METASTATIC PROSTATE CANCER PFIZER - TALZENNA PLUS XTAND
03-19 20:02
BRIEF-BP Australia Acknowledges ACCC’S Investigation Into Its Market Practices, Says Spokesperson
BRIEF-BP Australia Acknowledges ACCC’S Investigation Into Its Market Practices, Says Spokesperson March 19 (Reuters) - BP Australia: ACKNOWLEDGES ACCC’S INVESTIGATION INTO ITS MARKET PRACTICES, SAYS SPOKESPERSON REVIEWING THE CLAIMS RAISED BY ACCC, SAYS SPOKESPERSON Further company coverage: BP.L ((
03-19 09:22
ANALYSIS-Wall Street's bank capital victory in sight but hurdles remain
ANALYSIS-Wall Street's bank capital victory in sight but hurdles remain Big bank capital to fall slightly under revised rule drafts New drafts softer than 2023 versions, seen as industry win Banks may seek further adjustments due to uneven benefits Industry will have 90 days to provide feedback on p
03-18 18:00
GRAPHIC-Take Five: Deja vu?
GRAPHIC-Take Five: Deja vu? U.S. Fed, Bank of Canada rate decisions Wednesday Europe, Japan central banks meet Thursday Iran war keeps markets on edge LONDON, March 13 (Reuters) - War in the Middle East is driving up energy prices sharply and that puts central banks, scarred by 2022's inflation surg
03-13 15:29
BRIEF-Bristol Myers Reports Positive Phase 3 Results For Oral Mezigdomide In Relapsed Myeloma
BRIEF-Bristol Myers Reports Positive Phase 3 Results For Oral Mezigdomide In Relapsed Myeloma March 9 (Reuters) - Bristol-Myers Squibb Co BMY.N : BRISTOL MYERS SQUIBB ANNOUNCES POSITIVE PHASE 3 RESULTS FROM THE SUCCESSOR-2 STUDY OF ORAL MEZIGDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA BRISTOL-
03-09 19:14
BRIEF-Anthropic Says Will Challenge Any Supply Chain Risk Designation In Court
BRIEF-Anthropic Says Will Challenge Any Supply Chain Risk Designation In Court Feb 27 (Reuters) - ANTHROPIC: STATEMENT ON THE COMMENTS FROM SECRETARY OF WAR PETE HEGSETH ANTHROPIC: HAVE TRIED IN GOOD FAITH TO REACH AN AGREEMENT WITH THE DEPARTMENT OF WAR ANTHROPIC: TO THE BEST OF OUR KNOWLEDGE, THES
02-28 09:22
BRIEF-Bristol Myers Squibb Announces Positive Top-Line Results From Registrational Phase 2 Study Of Luspatercept
BRIEF-Bristol Myers Squibb Announces Positive Top-Line Results From Registrational Phase 2 Study Of Luspatercept Feb 23 (Reuters) - Bristol-Myers Squibb Co BMY.N : BRISTOL MYERS SQUIBB ANNOUNCES POSITIVE TOP-LINE RESULTS FROM REGISTRATIONAL PHASE 2 STUDY OF LUSPATERCEPT IN ADULTS WITH ALPHA (Α)-THAL
02-23 20:18
